We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
1367-P: Effect of Nationwide Reimbursement of Sensor-Augmented Pump (SAP) Therapy in a Paediatric Type 1 Diabetes (T1D) Population on HbA1c, Hypoglycaemia, and Quality of Life (QoL) According to Age Groups in the RESCUE-Paediatrics Study.
- Authors
DE RIDDER, FRANCESCA; JACOBS, SEPPE; CHARLEER, SARA; GILLARD, PIETER; CASTEELS, KRISTINA; VAN AKEN, SARA; GIES, INGE; MASSA, GUY; LYSY, PHILIPPE A.; LOGGHE, KARL; LEBRETHON, MARIE-CHRISTINE; DEPOORTER, SYLVIA; LEDEGANCK, KRISTIEN J.; DE BLOCK, CHRISTOPHE; BRINKER, MARIEKE DEN
- Abstract
Background: Long-term real-life data of SAP in pediatric T1D patients are scarce. Objectives: To assess the impact of 12 months use of SAP in a nationwide study of pediatric T1D patients on HbA1c, hypoglycemia and quality of life1 according to age. Methods: Between 12/2014 and 02/2017, 75 children entered Belgian reimbursement system for SAP and were followed for 12 months. Study endpoints included change in HbA1c at 0-4-8-12 months; time-in-hypoglycemia (<70mg/dl) and time-in-severe-hypoglycemia (<50mg/dl) (%/day) at 0-12 months; and QoL2 at 0-12 months. Puberty was defined as age ≥11.6y in boys and ≥11.2y in girls. Results: Seventy-three patients used SAP for 12 months. Baseline HbA1c (7.2±0.7%) decreased to 7.1±0.8% at 4 months (p=0.02), remained stable at 8 months (p=0.03) and 12 months (p=0.15). In pubertal children (n=29) baseline was 7.1±0.7%. It decreased to 6.8±0.7% at 4 months (p=0.003), increased to 7.0±0.8% at 8 months (p=0.02) and to 7.1±0.8% at 12 months (p=0.20). In prepubertal children (n=43) baseline Hb1Ac was 7.3±0.7%; and evolved towards 7.1±0.8% at 12 months (p=0.40). In pubertal children, time-in-hypoglycemia decreased from 7.1±6.9% to 5.7±5.1% (p=0.06) the first year, while time-in-severe-hypoglycemia did not significantly change (1.0±1.7% to 1.3±2.0%). In prepubertal children, both parameters did not significantly change (5,9±5,4% to 5,6±3,4% - 0,8±1,4% to 1,1±1,4%). In pubertal children and their parents, QoL did not significantly change. In prepubertal children, satisfaction scores improved after 12months from 67±12 to 70±9 (p=0.026). Conclusions: One year reimbursement of SAP in pediatric T1D patients improved HbA1c in the first 8 months in all; tended to decrease hypoglycemia in pubertal children; while improving QoL in prepubertal children. 1RESCUE-NCT02601729. 2Impact, satisfaction, worry (children) and parents. Disclosure: F. De Ridder: None. S. Jacobs: None. S. Charleer: Other Relationship; Self; Roche Diabetes Care. P. Gillard: None. K. Casteels: None. S. Van Aken: None. I. Gies: None. G. Massa: None. P.A. Lysy: None. K. Logghe: None. M. Lebrethon: None. S. Depoorter: None. K.J. Ledeganck: None. C. De Block: None. M. den Brinker: None.
- Publication
Diabetes, 2019, Vol 68, pN.PAG
- ISSN
0012-1797
- Publication type
Article
- DOI
10.2337/db19-1367-P